CHRONIC LYMPHOCYTIC LEUKEMIA

This study tests whether a two-shot pneumonia vaccine series (PCV20 and PPSV23) can help people with chronic lymphocytic leukemia (CLL) build a stronger immune defense against pneumococcal infections. About 61 participants with CLL, either untreated or on a specific drug, will re…

This study tests whether adding the drug epcoritamab after standard treatment can make chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) disappear more completely. About 22 adults who have already received at least 12 months of targeted therapy will get epcor…

This study tests whether the drug mosunetuzumab, given alone or with a BTK inhibitor, can clear tiny amounts of leftover leukemia cells in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 40 adults who are already on or have recently finis…

This early-phase trial tests an oral drug called AS-1763 in adults with certain blood cancers (like CLL or lymphoma) that have not responded to at least two prior treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. Around 120 participants…

This study offers ongoing access to the drug ibrutinib for people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. Researchers will track side effects and disease changes over time. About 700 particip…

This study looks at the long-term safety of pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in an earlier trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to track seri…

This study tests whether adding emavusertib to a standard targeted therapy (zanubrutinib) can better control chronic lymphocytic leukemia and related B-cell cancers. About 108 adults with these cancers will receive the combination. The goal is to see if the combo can make cancer …

This study tests whether giving two drugs—acalabrutinib and obinutuzumab—in cycles can control chronic lymphocytic leukemia (CLL) in people who have not yet been treated. The goal is to see if patients can stop treatment for a while without the cancer coming back. About 60 adults…

This study tests whether a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) can control chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back after prior treatment. About 40 adults with relapsed CLL/SLL will receive this time-limite…

This study tests a new drug, BGB-16673, against standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has already been treated with both BTK and BCL2 inhibitors. About 250 participants will be randomly assigned to …

This study tests a two-step method using lower doses of radiation and chemotherapy before a stem cell transplant for people with various blood cancers or bone marrow failure. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About…

This early-phase study tests azer-cel, a pre-made (allogeneic) CAR T cell therapy, in adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and related blood cancers. The goal is to check safety and see if these donor-derived cells can shri…

This study is for people with certain blood cancers (like CLL or lymphoma) who are starting a type of drug called a BTK inhibitor. These drugs can raise blood pressure and increase the risk of heart problems. The study will test if carefully managing high blood pressure can lower…

This study tests two drug combinations—acalabrutinib plus venetoclax or obinutuzumab—in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see if these combinations can shrink tumors and reduce cancer cells to undetectable level…

This study tests a drug called glofitamab, alone or with other medicines, for people with a rare and aggressive form of blood cancer called Richter's transformation. The goal is to see if the treatment can shrink or eliminate the cancer. About 70 adults with this condition will t…

This study tests an experimental oral drug called LP-118 in up to 100 adults with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or not responded to other treatments. The main goals are to find the safest dose and see if the drug can shrink tumors …

This study tests whether adding a new drug called roginolisib to two standard drugs (venetoclax and rituximab) is safe and works better for people with CLL that has come back or not responded to prior treatments. About 64 adults who have already tried at least two other therapies…

This early-stage study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not improved with standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system attack c…

This study tests a combination of three drugs (venetoclax, obinutuzumab, and possibly acalabrutinib) in people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or not responded to prior treatment. The goal is to see if the treatment can eliminate…

This study compares starting treatment right away versus waiting until symptoms appear in people with newly diagnosed, high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Participants receive a combination of two drugs: venetoclax (which blocks a protein that he…

This study tests whether adding obinutuzumab to acalabrutinib works better than acalabrutinib alone for people with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are at high risk of their disease getting worse. About 120 adults will be ran…

This study compares an experimental drug, BGB-16673, to an approved drug, pirtobrutinib, in about 500 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer returned or didn't respond after prior treatment with a BTK inhibitor. The main go…

This study tests different ways to start the drug venetoclax (combined with either obinutuzumab or acalabrutinib) in people with untreated chronic lymphocytic leukemia (CLL). The goal is to find a dosing schedule that lowers the risk of a dangerous side effect called tumor lysis …

This phase 3 study compares two drug combinations for people with untreated chronic lymphocytic leukemia (CLL). One group gets sonrotoclax plus zanubrutinib, the other gets venetoclax plus acalabrutinib. The goal is to see which combo works better at controlling the disease and c…

This study tests a new drug combination (polatuzumab vedotin plus chemotherapy) in 20 adults with Richter's transformation, an aggressive lymphoma that can develop from chronic lymphocytic leukemia. Participants receive up to six cycles of treatment and are monitored for safety a…

This study tests a faster way to increase the dose of sonrotoclax, a drug that blocks a protein helping cancer cells survive. It is given after initial treatment with zanubrutinib or rituximab. The trial includes 30 adults with chronic lymphocytic leukemia, small lymphocytic lymp…

This early-phase study tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphoma and leukemia). The main goals are to check safety and find the best dose. Participants will receive the drug and be monitored for side effects and how the d…

This study tests a new immune therapy for people with advanced B-cell lymphoma or leukemia that has returned or not responded to standard treatment. Researchers take a patient's own T-cells, add a special receptor (CAR) that targets the CD19 protein on cancer cells, and give them…

This study tests whether combining two targeted drugs, pirtobrutinib and venetoclax, can kill more cancer cells in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose disease progressed despite standard BTK inhibitor therapy. About 30 adults w…

This study tests an experimental drug called BGB-16673 in people with several types of B-cell cancers (like lymphoma and leukemia) that have come back or not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The tri…

This study is for people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. It tests a one-year treatment with two drugs, pirtobrutinib and obinutuzumab, to see how well they control the disease. About 60 participants will receive the therapy for 12 cycles…

This study looks at two different schedules of a drug combination (venetoclax and acalabrutinib) for people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 62 participants will either take venetoclax continuously or only for part of the time, to s…

This early-stage trial tests the safety and effectiveness of combining three drugs (tafasitamab, acalabrutinib, and obinutuzumab) in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study involves 27 adults who will rece…

This study tests a new drug called BGB-16673 in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer returned or stopped responding after treatment with a BTK inhibitor. About 150 participants will receive either BGB-16673 or one of two …

This study tests whether adding venetoclax to ongoing ibrutinib or acalabrutinib treatment can clear remaining leukemia cells in people with high-risk chronic lymphocytic leukemia (CLL). Participants must have been on ibrutinib or acalabrutinib for at least 12 months and still ha…

This study tests a new type of CAR T-cell therapy for adults with B-cell lymphoma or leukemia that has come back or not responded to treatment. The therapy uses a patient's own immune cells that are specially trained to find and attack cancer cells. The main goals are to find the…

This large Phase 3 study compares a new drug, nemtabrutinib, with two standard treatments (ibrutinib or acalabrutinib) for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have not yet received any therapy. The goal is to see if nemtabrutinib works as we…

This early-stage study tests an experimental drug called ABBV-319 in adults with B-cell lymphomas or chronic lymphocytic leukemia that has come back or not responded to treatment. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 1…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia or non-Hodgkin lymphoma. Participants have already completed an earlier pirtobrutinib study and can continue treatment or follow-up visits here. The main goal is to trac…

This study tests whether adding a drug called epcoritamab to the usual two-drug treatment (venetoclax and obinutuzumab) can make cancer disappear more completely in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 33 adults will …

This study tests whether a combination of three drugs (acalabrutinib, venetoclax, and durvalumab) can help people with Richter transformation, a rare and aggressive lymphoma that develops from chronic lymphocytic leukemia (CLL). The drugs work by blocking cancer growth signals, t…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with a BTK inhibitor. It is open to 150 adults who completed a previous related study. Participan…

This early-stage study tests an experimental drug called CC312 in about 44 adults with certain blood cancers (like lymphoma or leukemia) that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. Research…

This study compares a newer targeted drug, pirtobrutinib, to an older one, ibrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 662 participants will be enrolled, some who have had prior treatment and some who have not. The goal …

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and sonrotoclax) in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The main goal is to see if the treatment can make the cancer undetectable in the blood. Abo…

This study tests a new drug called APG-2575 in people whose chronic lymphocytic leukemia or small lymphocytic lymphoma has come back or stopped responding to other treatments. About 75 adults will take the drug alone to see if it shrinks tumors and how safe it is. The goal is to …

This study tests whether taking nicotinamide (a form of vitamin B3) twice daily can lower the risk of new non-melanoma skin cancers in people with chronic lymphocytic leukemia (CLL) who have already had at least one skin cancer. About 86 participants will be randomly assigned to …

This study tests a new drug, sonrotoclax, combined with antibody therapy for adults with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma. About 630 participants will be randomly assigned to receive either the new combination or a standard trea…

This study tests three different doses of an experimental drug called pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer came back or didn't respond to a previous type of targeted therapy (a BTK inhibitor). The goal is…

This early-stage study is for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to standard treatments. Researchers are testing a drug called mosunetuzumab, either alone or combined with another drug (venetoclax), to see if they are safe and …

This study is for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already taking a BTKi pill (like ibrutinib). It compares staying on the BTKi pill alone versus adding a second pill, venetoclax, for one year and then stopping both. The g…

This study tests two drugs together for people with Richter transformation, a fast-growing lymphoma that can arise from chronic lymphocytic leukemia. The drugs aim to block cancer growth and help the immune system attack the cancer. About 32 adults who have not responded to or ca…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after transplant. About 46 people with various blood cancers or disorders will take part. The goal i…

This study tests whether giving yearly pneumococcal vaccines to people with chronic lymphocytic leukemia (CLL) offers better protection than the current standard of revaccination every 5 years. About 80 adults with untreated CLL will receive either an initial vaccine followed by …

This study tests whether giving a CMV vaccine to stem cell donors can protect transplant recipients from CMV infection. Donors receive the vaccine before donating stem cells, and the immunity is passed to the patient. The trial involves 216 people with blood cancers and aims to r…

This study looks at the costs and quality of life for people with high-risk chronic lymphocytic leukemia (CLL) who start treatment early versus waiting. Researchers will track medical visits, tests, and hospital stays over 10 years. The goal is to find out which approach gives th…

This study aims to learn more about the causes and biology of chronic lymphocytic leukemia (CLL) by collecting tissue samples and medical information from 2,750 participants. It is open to new and existing patients with CLL or related low-grade lymphoproliferative disorders. The …

This study is gathering basic health and survival information from 2000 people who are getting a stem cell transplant for blood cancers or immune diseases. The goal is to build a database that doctors can use to improve care and answer future questions. No experimental treatments…

This study aims to understand how chronic lymphocytic leukemia (CLL) cells use nutrients like glucose and glutamine compared to normal cells. Researchers will give participants a special tracer nutrient and analyze blood samples to map metabolic activity. The goal is to find new …

This study is for people starting a type of cancer drug called BTK inhibitors, which can sometimes cause irregular heartbeats. Researchers will implant a small heart monitor under the skin to watch for these heart rhythm problems. The goal is to learn how often these problems hap…

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of mu…

This study looks at how two blood conditions—monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)—affect the bone marrow's ability to fight infections. Researchers will compare bone marrow samples from 50 participants, including people with MBL, people wit…

This study aims to understand why some people with chronic lymphocytic leukemia (CLL) do not respond to a newer type of drug called BTK degraders. Researchers will collect blood, bone marrow, or lymph node samples from 60 patients over 9 years and follow them for 5 years. By stud…

This study measures how chronic lymphocytic leukemia (CLL) patients feel and function while taking acalabrutinib in everyday life, not just in a controlled trial. Researchers will look at quality-of-life scores from treatment start up to 12 months later, using data from 120 Frenc…

This study watches 50 adults with chronic lymphocytic leukemia (CLL) who are starting acalabrutinib alone (no other cancer drugs) to see how long they stay on treatment and why they might stop. It aims to fill a knowledge gap by collecting real-world data on effectiveness and saf…

This study follows 2,000 people with chronic lymphocytic leukemia (CLL) to see how the order of treatments affects how long they live. It does not test new drugs but watches patients who already received standard first-line treatments in earlier studies. The goal is to find which…

This study looks at whether CAR-T cell therapy, a treatment for certain blood cancers, reduces the protection that past vaccines (like measles or tetanus shots) provide. Researchers will test the blood of 45 adults with multiple myeloma or non-Hodgkin lymphoma before and after CA…

This study looks at how the immune system of people with lymphoma responds to flu and COVID vaccines. Researchers will measure antibody levels and immune cells in 200 participants with different types of lymphoma and compare them to healthy individuals. The goal is to understand …

This study is observing adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking the drug zanubrutinib. Researchers want to see how often patients need hospital care and how their quality of life chan…

This study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…

This study looks at genetic changes in chronic lymphocytic leukemia (CLL) patients during treatment with the drug venetoclax. Researchers want to understand how the drug affects cancer cells and the immune system. The study involves 75 adults with relapsed or refractory CLL who w…